Completed PHASE2 INTERVENTIONAL 2-arm NCT00235898

Clinical Trial in Patients With Metastatic Colorectal Cancer

A Multi-Center, Open Label, Parallel Group, Randomised, Phase IIB Clinical Trial to Evaluate the Safety and Efficacy of CoFactor and 5-FU Versus Leucovorin and 5-FU in Subjects With Metastatic Colorectal Carcinoma

Sponsor: Mast Therapeutics, Inc.

Conditions Colon Cancer Rectal Cancer

Interventions 5-FU CoFactor Leucovorin

Updated 7 times since 2017 Last updated: Aug 22, 2008 Started: May 31, 2005 Primary completion: Mar 31, 2008

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00235898, this PHASE2 trial focuses on Colon Cancer and Rectal Cancer and remains completed. Sponsored by Mast Therapeutics, Inc., it has been updated 7 times since 2005, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

Change History

7 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE2
Sep 2024 — Sep 2025 [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2
Jun 2018 — Jan 2021 [monthly]

Completed PHASE2

▶ Show 2 earlier versions

Feb 2017 — Jun 2018 [monthly]

Completed PHASE2
Jan 2017 — Feb 2017 [monthly]

Completed PHASE2

First recorded

May 2005

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Mast Therapeutics, Inc.

Data source: Mast Therapeutics, Inc.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Bangalore, India , Belgrade, Serbia , Bucharest, Romania , Cluj-Napoca, Romania , Gdansk, Poland , Gdynia Redlowo, Poland , Glasgow, United Kingdom , Harlow, United Kingdom , Hyderabad, India , Jaipur, India and 15 more locations